In the absence of relevant data, the prevalence of cardiac autonomic neuropathy was investigated ... more In the absence of relevant data, the prevalence of cardiac autonomic neuropathy was investigated in patients with diabetes mellitus or uremia due to other causes and diabetic patients with endstage renal failure. 117 patients (40 on a dialysis program without diabetes, 32 with diabetes mellitus type 1 but no nephropathy, 16 type 1 and 13 type 2 diabetic uremic patients, 16 diabetic patients with a kidney graft) and 25 healthy control subjects underwent assessment of the cardiorespiratory reflexes. The evaluation of parasympathetic damage was of particular interest. Definite parasympathetic dysfunction was detected in 32% of the non-diabetic uremic and in 19% of the non-uremic type 1 diabetic patients. Furthermore, 88% of type 1 and 77% of type 2 diabetic patients on dialysis and 75% of diabetic patients after kidney transplantation had evidence of autonomic neuropathy.
19. Yang T, Nast CC, Vo A et al. Rapid remission of steroid and mycophenolate mofetil (MMF)-resis... more 19. Yang T, Nast CC, Vo A et al. Rapid remission of steroid and mycophenolate mofetil (MMF)-resistant minimal change ne-phrotic syndrome after rituximab therapy. Nephrol Dial Trans-plant 2008; 23: 377–380 20. Peters HP, van de Kar NC, Wetzels JF. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature. Neth J Med 2008; 66: 408–415 21. Smith GC. Is there a role for rituximab in the treatment of idio-pathic childhood nephritic syndrome? Pediatr Nephrol 2007; 22: 893–898 22. Kurosu N, Sugiura H, Iwasaki C et al. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern Med 2009; 48: 1901–1904 23. Sawara Y, Itabashi M, Kojima C et al. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. Clin Nephrol 2009; 72: 69–72 24. Sugiura H, Takei T, Itabashi M et al. Effect of single-...
Numerous studies have investigated Iipoprotein(a) (Lp(a)) plasma concentrations in patients with ... more Numerous studies have investigated Iipoprotein(a) (Lp(a)) plasma concentrations in patients with ESRD, a patient group with an enormous risk for atherosclerosis. The reported differences in Lp(a) between controls and patients vary from a decrease of 49 % to an increase of more than 1,000%. However, data are not consistent, mostly because of problems with statistical analysis, and only limited data are available for patients treated by continuous ambulatory peritoneal dialysis (CAPD). To estimate the significance of Lp(a) in ESRD and to demonstrate the statistical piffalls concerning Lp(a) in case-control studies, a large multicenter study including 702 patients treated by either hemodialysis (HD) (N = 534) or CAPD (N = 168) was conducted, and results were compared with results from 256 healthy controls. Both patient groups showed significantly elevated Lp(a) levels in comparison with controls: 23.4 ± 25.0 mg/dL (P < 0.005; HD) and 34.6 ± 38.4 mg/dL (P< 0.0001; CAPD) versus 18....
Background. Calciphylaxis is a life-threatening compli-cation in patients with end-stage renal di... more Background. Calciphylaxis is a life-threatening compli-cation in patients with end-stage renal disease (ESRD). No established therapy exists so far. The aim of the present study was to determine the therapeutic response to a multi-interventional treatment regimen with consistent use of sodium thiosulphate (STS) in an Austrian cohort of calciphylaxis patients. Methods. We retrospectively collected demographic, clinical and laboratory data on 27 calciphylaxis patients treated with STS at seven Austrian dialysis centres
Numerous studies have investigated Iipoprotein(a) (Lp(a)) plasma concentrations in patients with ... more Numerous studies have investigated Iipoprotein(a) (Lp(a)) plasma concentrations in patients with ESRD, a patient group with an enormous risk for atheroscle- rosis. The reported differences in Lp(a) between con- trols and patients vary from a decrease of 49% to an increase of more than 1,000%. However, data are not consistent, mostly because of problems with statistical analysis, and only limited
Diabetes mellitus is the leading single cause for renal replacement therapy. Its development and ... more Diabetes mellitus is the leading single cause for renal replacement therapy. Its development and progression, however, can be ameliorated by adequate therapy. The present article represents the recommendations of the Austrian Diabetes Association for the prevention and treatment of diabetic nephropathy.
Experimental and Clinical Endocrinology & Diabetes, 2010
Post-transplant-diabetes-mellitus (PTDM) is a frequent complication after kidney transplantation.... more Post-transplant-diabetes-mellitus (PTDM) is a frequent complication after kidney transplantation. One-hundred-and-seven patients with kidney transplantation were screened for the occurrence of PTDM. Of these, full data sets from 49 subjects were available with documented glucose concentrations during maintenance hemodialysis (MHD) and regular clinical follow-up of 7-34 months. For assessment of glucose metabolism the response to a standard meal during MHD was used in normoglycemic patients based on fasting blood glucose. Abnormal postprandial blood glucose concentration was defined as &amp;amp;gt;140 mg/dl 2 h after food intake.Twelve end stage renal disease patients had abnormal postprandial blood glucose on MHD. All 12 subjects but also four MHD patients with normal postprandial and fasting blood glucose values developed PTDM. Multivariate Cox-regression analysis revealed that abnormal postprandial blood glucose is a strong predictor for PTDM (Hazard ratio: 42.3 (IQR: 7.9-227.2); p&amp;amp;lt;0.001). Fasting blood glucose (94 vs. 100 mg/dl) was not different between MHD patients who did (n=16) or did not (n=33) develop PTDM.This study suggests that measurement of postprandial blood glucose during MHD identifies patients who develop PTDM after kidney transplantation. It should be used for screening of patients at risk.
Zusammenfassung Rezente epidemiologische Untersuchungen zeigen, dass etwa 2-3 % aller Österreiche... more Zusammenfassung Rezente epidemiologische Untersuchungen zeigen, dass etwa 2-3 % aller Österreicher Diabetes mit Nierenbeteiligung aufweisen. Diese betrifft somit in Österreich etwa 250.000 Menschen. Das Risiko des Auftretens und Fortschreitens der Erkrankung kann durch Lebensstilinterventionen und Optimierung der Einstellung des Blutdrucks, Blutzuckers und spezielle Medikamentenklassen vermindert werden. In diesem gemeinsamen Artikel der H. Sourij ( ) Klinische
Diabetes mellitus is the leading single cause for renal replacement therapy. Its development and ... more Diabetes mellitus is the leading single cause for renal replacement therapy. Its development and progression, however, can be ameliorated by adequate therapy. The present article represents the recommendations of the Austrian Diabetes Association and the Austrian Society for Nephrology for the prevention and treatment of diabetic nephropathy.
Recent epidemiological evaluations have shown that approximately 5 % of all Austrians suffer from... more Recent epidemiological evaluations have shown that approximately 5 % of all Austrians suffer from diabetes including renal involvement, i. e. 400.000 people in Austria are affected. The risk of start and progression of this disease can be ameliorated by lifestyle interventions as well as optimization of blood pressure and glucose levels. The present article represents the joint recommendations of the Austrian Diabetes Association and the Austrian Society for Nephrology for the prevention and treatment of diabetic kidney disease.
Journal of the American Society of Nephrology, May 1, 1999
Patients with end-stage renal disease treated by hemodialysis have a tremendous risk for cardiova... more Patients with end-stage renal disease treated by hemodialysis have a tremendous risk for cardiovascular complications that cannot be explained by traditional atherosclerosis risk factors. Lipoprotein(a) (Lp(a)), a risk factor for these complications in the general population, is significantly elevated in these patients. In this study, it was determined whether Lp(a) and/or the genetically determined apo(a) phenotype are risk predictors for the development of coronary artery disease in these patients. A cohort of 440 unselected hemodialysis patients were followed for a period of 5 yr independent of the cause of renal disease, duration of preceding treatment, and the preexistence of coronary artery disease at study entry. Coronary events defined as definite myocardial infarction, percutaneous transluminal coronary angioplasty, aortocoronary bypass, or a stenosis Ͼ50% in the coronary angiography were the main outcome measure. Sixty-six (15%) of the 440 patients suffered a coronary event during follow-up. In univariate analysis, patients with events were significantly older and showed
In the absence of relevant data, the prevalence of cardiac autonomic neuropathy was investigated ... more In the absence of relevant data, the prevalence of cardiac autonomic neuropathy was investigated in patients with diabetes mellitus or uremia due to other causes and diabetic patients with endstage renal failure. 117 patients (40 on a dialysis program without diabetes, 32 with diabetes mellitus type 1 but no nephropathy, 16 type 1 and 13 type 2 diabetic uremic patients, 16 diabetic patients with a kidney graft) and 25 healthy control subjects underwent assessment of the cardiorespiratory reflexes. The evaluation of parasympathetic damage was of particular interest. Definite parasympathetic dysfunction was detected in 32% of the non-diabetic uremic and in 19% of the non-uremic type 1 diabetic patients. Furthermore, 88% of type 1 and 77% of type 2 diabetic patients on dialysis and 75% of diabetic patients after kidney transplantation had evidence of autonomic neuropathy.
19. Yang T, Nast CC, Vo A et al. Rapid remission of steroid and mycophenolate mofetil (MMF)-resis... more 19. Yang T, Nast CC, Vo A et al. Rapid remission of steroid and mycophenolate mofetil (MMF)-resistant minimal change ne-phrotic syndrome after rituximab therapy. Nephrol Dial Trans-plant 2008; 23: 377–380 20. Peters HP, van de Kar NC, Wetzels JF. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature. Neth J Med 2008; 66: 408–415 21. Smith GC. Is there a role for rituximab in the treatment of idio-pathic childhood nephritic syndrome? Pediatr Nephrol 2007; 22: 893–898 22. Kurosu N, Sugiura H, Iwasaki C et al. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern Med 2009; 48: 1901–1904 23. Sawara Y, Itabashi M, Kojima C et al. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. Clin Nephrol 2009; 72: 69–72 24. Sugiura H, Takei T, Itabashi M et al. Effect of single-...
Numerous studies have investigated Iipoprotein(a) (Lp(a)) plasma concentrations in patients with ... more Numerous studies have investigated Iipoprotein(a) (Lp(a)) plasma concentrations in patients with ESRD, a patient group with an enormous risk for atherosclerosis. The reported differences in Lp(a) between controls and patients vary from a decrease of 49 % to an increase of more than 1,000%. However, data are not consistent, mostly because of problems with statistical analysis, and only limited data are available for patients treated by continuous ambulatory peritoneal dialysis (CAPD). To estimate the significance of Lp(a) in ESRD and to demonstrate the statistical piffalls concerning Lp(a) in case-control studies, a large multicenter study including 702 patients treated by either hemodialysis (HD) (N = 534) or CAPD (N = 168) was conducted, and results were compared with results from 256 healthy controls. Both patient groups showed significantly elevated Lp(a) levels in comparison with controls: 23.4 ± 25.0 mg/dL (P < 0.005; HD) and 34.6 ± 38.4 mg/dL (P< 0.0001; CAPD) versus 18....
Background. Calciphylaxis is a life-threatening compli-cation in patients with end-stage renal di... more Background. Calciphylaxis is a life-threatening compli-cation in patients with end-stage renal disease (ESRD). No established therapy exists so far. The aim of the present study was to determine the therapeutic response to a multi-interventional treatment regimen with consistent use of sodium thiosulphate (STS) in an Austrian cohort of calciphylaxis patients. Methods. We retrospectively collected demographic, clinical and laboratory data on 27 calciphylaxis patients treated with STS at seven Austrian dialysis centres
Numerous studies have investigated Iipoprotein(a) (Lp(a)) plasma concentrations in patients with ... more Numerous studies have investigated Iipoprotein(a) (Lp(a)) plasma concentrations in patients with ESRD, a patient group with an enormous risk for atheroscle- rosis. The reported differences in Lp(a) between con- trols and patients vary from a decrease of 49% to an increase of more than 1,000%. However, data are not consistent, mostly because of problems with statistical analysis, and only limited
Diabetes mellitus is the leading single cause for renal replacement therapy. Its development and ... more Diabetes mellitus is the leading single cause for renal replacement therapy. Its development and progression, however, can be ameliorated by adequate therapy. The present article represents the recommendations of the Austrian Diabetes Association for the prevention and treatment of diabetic nephropathy.
Experimental and Clinical Endocrinology & Diabetes, 2010
Post-transplant-diabetes-mellitus (PTDM) is a frequent complication after kidney transplantation.... more Post-transplant-diabetes-mellitus (PTDM) is a frequent complication after kidney transplantation. One-hundred-and-seven patients with kidney transplantation were screened for the occurrence of PTDM. Of these, full data sets from 49 subjects were available with documented glucose concentrations during maintenance hemodialysis (MHD) and regular clinical follow-up of 7-34 months. For assessment of glucose metabolism the response to a standard meal during MHD was used in normoglycemic patients based on fasting blood glucose. Abnormal postprandial blood glucose concentration was defined as &amp;amp;gt;140 mg/dl 2 h after food intake.Twelve end stage renal disease patients had abnormal postprandial blood glucose on MHD. All 12 subjects but also four MHD patients with normal postprandial and fasting blood glucose values developed PTDM. Multivariate Cox-regression analysis revealed that abnormal postprandial blood glucose is a strong predictor for PTDM (Hazard ratio: 42.3 (IQR: 7.9-227.2); p&amp;amp;lt;0.001). Fasting blood glucose (94 vs. 100 mg/dl) was not different between MHD patients who did (n=16) or did not (n=33) develop PTDM.This study suggests that measurement of postprandial blood glucose during MHD identifies patients who develop PTDM after kidney transplantation. It should be used for screening of patients at risk.
Zusammenfassung Rezente epidemiologische Untersuchungen zeigen, dass etwa 2-3 % aller Österreiche... more Zusammenfassung Rezente epidemiologische Untersuchungen zeigen, dass etwa 2-3 % aller Österreicher Diabetes mit Nierenbeteiligung aufweisen. Diese betrifft somit in Österreich etwa 250.000 Menschen. Das Risiko des Auftretens und Fortschreitens der Erkrankung kann durch Lebensstilinterventionen und Optimierung der Einstellung des Blutdrucks, Blutzuckers und spezielle Medikamentenklassen vermindert werden. In diesem gemeinsamen Artikel der H. Sourij ( ) Klinische
Diabetes mellitus is the leading single cause for renal replacement therapy. Its development and ... more Diabetes mellitus is the leading single cause for renal replacement therapy. Its development and progression, however, can be ameliorated by adequate therapy. The present article represents the recommendations of the Austrian Diabetes Association and the Austrian Society for Nephrology for the prevention and treatment of diabetic nephropathy.
Recent epidemiological evaluations have shown that approximately 5 % of all Austrians suffer from... more Recent epidemiological evaluations have shown that approximately 5 % of all Austrians suffer from diabetes including renal involvement, i. e. 400.000 people in Austria are affected. The risk of start and progression of this disease can be ameliorated by lifestyle interventions as well as optimization of blood pressure and glucose levels. The present article represents the joint recommendations of the Austrian Diabetes Association and the Austrian Society for Nephrology for the prevention and treatment of diabetic kidney disease.
Journal of the American Society of Nephrology, May 1, 1999
Patients with end-stage renal disease treated by hemodialysis have a tremendous risk for cardiova... more Patients with end-stage renal disease treated by hemodialysis have a tremendous risk for cardiovascular complications that cannot be explained by traditional atherosclerosis risk factors. Lipoprotein(a) (Lp(a)), a risk factor for these complications in the general population, is significantly elevated in these patients. In this study, it was determined whether Lp(a) and/or the genetically determined apo(a) phenotype are risk predictors for the development of coronary artery disease in these patients. A cohort of 440 unselected hemodialysis patients were followed for a period of 5 yr independent of the cause of renal disease, duration of preceding treatment, and the preexistence of coronary artery disease at study entry. Coronary events defined as definite myocardial infarction, percutaneous transluminal coronary angioplasty, aortocoronary bypass, or a stenosis Ͼ50% in the coronary angiography were the main outcome measure. Sixty-six (15%) of the 440 patients suffered a coronary event during follow-up. In univariate analysis, patients with events were significantly older and showed
Uploads
Papers by Martin Auinger